文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌术后单次立体定向部分乳腺照射:GammaPod II期临床试验

Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-10-27

这项单中心前瞻性II期试验纳入148例早期乳腺癌保乳术后患者,采用GammaPod行单次17.5 Gy立体定向部分乳腺照射。中位随访24.9个月,≥3级毒性未见,2年局部复发率1.8%,耐受性和早期肿瘤控制良好。

要点

  • 单次17.5 Gy GammaPod部分乳腺照射耐受性好,无≥3级毒性。
  • 2年局部复发率1.8%,区域复发率0.8%, locoregional复发率1.8%。
  • 2级纤维化发生率3.3%,1级纤维化36.5%。

核心结论

  • 单次立体定向部分乳腺照射耐受性极好,早期肿瘤控制令人鼓舞,可能成为多分次方案的高效替代。

研究设计与样本

  • 前瞻性单中心II期临床试验,2022年1月至2024年5月纳入148例保乳术后早期乳腺癌患者。
  • 处方单次17.5 Gy至95%计划靶区,俯卧位使用GammaPod专用立体定向放疗设备。

主要发现

  • 中位年龄68岁(IQR 58-74),中位随访24.9个月(IQR 18.3-33.7),全部患者随访至少12个月。
  • 手术至放疗中位时间2.5个月(IQR 2.1-2.9),中位计划靶区体积43.6 cc。
  • 2级纤维化5例(3.3%),无≥3级毒性;3、6、12个月2级纤维化发生率分别为0.7%、2%、3.4%,1级纤维化36.5%。
  • 24个月局部复发率1.8%,区域复发率0.8%, locoregional复发率1.8%。

关键数值与推荐

  • 主要终点为急性毒性(照射后3个月内)累积发生率和照射后2年中重度晚期毒性。
  • 次要终点包括局部复发、区域复发和 locoregional复发。

临床怎么用

  • 对于早期乳腺癌保乳术后患者,单次GammaPod部分乳腺照射提供了一种高效、患者友好的治疗选择。
  • 需等待与5分次部分乳腺照射方案正在进行的随机对照比较结果,以进一步明确其临床定位。

局限性

  • 单中心、单臂设计,随访时间有限(中位24.9个月)。
  • 缺乏与多分次方案的随机对照数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the feasibility, safety, and preliminary oncologic outcomes of postoperative single-fraction stereotactic partial breast irradiation (S-PBI) delivered with the GammaPod system in patients with early-stage breast cancer. METHODS AND MATERIALS: This prospective, single-institution phase 2 trial enrolled 148 patients who received breast-conserving surgery followed by S-PBI. Treatment consisted of a single 17.5-Gy fraction prescribed to 95% of the planning target volume, delivered in prone position using GammaPod, a dedicated stereotactic radiation therapy device. The primary objectives of the study were the cumulative incidence of acute toxicity (within 3 months from S-PBI) and moderate-to-severe late toxicity at 2 years following S-PBI. Secondary objectives include assessing local recurrence, regional recurrence, and locoregional recurrence. RESULTS: Between January 2022 and May 2024, 148 patients were enrolled. The median age at diagnosis was 68 years (IQR, 58-74). Median follow-up was 24.9 months (IQR, 18.3-33.7). All patients had a minimum follow-up of 12 months. The median time from surgery to radiation was 2.5 months (IQR, 2.1-2.9). Most tumors were pT1, pN0, hormone receptor-positive. The median planning target volume was 43.6 cc. Grade 2 fibrosis occurred in 5 patients (3.3%), with no grade ≥3 toxicities. The incidence rate of grade 2 fibrosis at 3, 6, and 12 months was 0.7%, 2%, and 3.4%, respectively. Grade 1 fibrosis was reported in 36.5% of patients. Local recurrence, regional recurrence, and locoregional recurrence rates at 24 months were 1.8%, 0.8%, and 1.8%, respectively. CONCLUSIONS: Single-fraction S-PBI using GammaPod was associated with excellent tolerability and promising early oncologic control in early breast cancer. With minimal late toxicity, this approach offers an efficient, patient-friendly alternative to multifraction regimens. Ongoing randomized comparison with a 5-fraction PBI schedule will further define its role in clinical practice.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Facondo G, Reverberi C, Prisco A, et al. Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41161644. doi:10.1016/j.ijrobp.2025.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。